Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
CME Activity
Safety of Biologic Therapies
Course Directors
Leonard Calabrese, DO
Department of Rheumatic & Immunologic Diseases
Cleveland Clinic
Cleveland, OH
Gregg J. Silverman, MD
Professor of Medicine
Director, Laboratory of B-Cell Immunology
Division of Rheumatology, Allergy, and Immunology
University of California San Diego School of Medicine
La Jolla, CA
Faculty
Jonathan Kay, MD
Director, Clinical Trials
Rheumatology Unit
Massachusetts General Hospital
Associate Clinical Professor of Medicine
Harvard Medical School
Boston, MA
Accredited by
Cleveland Clinic Center for Continuing Education
View Activity Materials
Course Description
Learning Objectives
1. Compare the safety profiles of B cell-depleting therapies in clinical trials of rheumatoid arthritis (RA), using rituximab and ofatumumab, and systemic lupus erythematosus (SLE), looking at belimumab and epratuzumab.
2. Evaluate safety of rituximab in RA patients with comorbidities.
3. Assess risk of malignancy in RA patients treated with TNF inhibitors.
4. Summarize recent safety data from clinical trials of tocilizumab in the treatment of RA.
Activity Details
| Credit Types: | CME |
| Credit Amount: | 0.5 Credits |
| Release Date: | 2011-Nov-10 |
| Expiration Date: | 2012-Nov-10 |
| Estimated Time for Completion: | 30 minutes |
| Registration Required: | No |
| Cost: | Free |
Search
Suggest a CME Activity
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
OpenCME for Publishers
Please use the form below if you would like to offer your website visitors high quality CME content by adding the OpenCME Widget to one or more of your pages.
